Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Oric Pharmaceuticals (ORIC) EBIAT (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of EBIAT readings, the most recent being -$35.8 million for Q1 2026.

  • Quarterly EBIAT fell 19.14% to -$35.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$135.2 million through Mar 2026, down 1.77% year-over-year, with the annual reading at -$129.5 million for FY2025, 1.27% down from the prior year.
  • EBIAT hit -$35.8 million in Q1 2026 for Oric Pharmaceuticals, down from -$30.5 million in the prior quarter.
  • Across five years, EBIAT topped out at -$20.3 million in Q2 2022 and bottomed at -$36.4 million in Q2 2025.
  • Average EBIAT over 5 years is -$28.4 million, with a median of -$28.3 million recorded in 2023.
  • The largest annual shift saw EBIAT crashed 40.28% in 2022 before it increased 15.98% in 2025.
  • Oric Pharmaceuticals' EBIAT stood at -$20.8 million in 2022, then plummeted by 35.89% to -$28.3 million in 2023, then dropped by 28.16% to -$36.3 million in 2024, then grew by 15.98% to -$30.5 million in 2025, then dropped by 17.25% to -$35.8 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's EBIAT are -$35.8 million (Q1 2026), -$30.5 million (Q4 2025), and -$32.6 million (Q3 2025).